title: Rationale use of GLP-1 receptor agonists in patients with type 1 diabetes.
abstract: Clinicians and patients are rapidly adapting GLP-1 receptor agonists as efficacious and safe therapeutic options for managing type 2 diabetes (T2DM). GLP-1 receptor agonists stimulate insulin production and secretion from the pancreatic β cells in a glucose-dependent manner, improve gastric emptying, favor weight reduction, and reduce postabsorptive glucagon secretion from pancreatic α cells. GLP-1 receptor activity is impaired in patients with T2DM. GLP-1 secretion and subsequent physiologic actions in patients with type 1 diabetes (T1DM) is ill-defined. Some researchers have suggested that the use of GLP-1 receptor agonists in T1DM may reduce excessive postprandial glucagon secretion allowing patients to reduce their total daily dose of exogenous insulin. Hypoglycemia risk may also be minimized in T1DM as glucagon counter-regulation can be preserved to some degree via the glucose-dependent action of the GLP-1 receptor agonists. This paper will consider the physiologic and pharmacologic benefits of adding GLP-1 receptor agonists to therapeutic regimens of patients with T1DM.
authors: Unger Primary Care, 14726 Ramona Ave, Suite 110, Chino, CA, 91710, USA, jungermd@aol.com.
authors: Jeff
authors: J
authors: Unger
mesh_terms: D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D052216:Glucagon-Like Peptide 1 / Q000494:pharmacology / Q000627:therapeutic use; D000067757:Glucagon-Like Peptide-1 Receptor; D006801:Humans; D007003:Hypoglycemia / Q000150:complications; D056687:Off-Label Use; D018027:Receptors, Glucagon / Q000819:agonists* / Q000172:deficiency
chemical_list: C000593833:GLP1R protein, human; D000067757:Glucagon-Like Peptide-1 Receptor; D018027:Receptors, Glucagon; D052216:Glucagon-Like Peptide 1
references: Diabetes Care. 2011 Nov;34(11):2368-73
references: 22025782
references: Science. 1973 Oct 12;182(4108):171-3
references: 4581053
references: J Clin Endocrinol Metab. 1965 Oct;25(10):1317-24
references: 5320560
references: Mayo Clin Proc. 2010 Dec;85(12 Suppl):S38-49
references: 21106866
references: BMJ. 2004 Mar 27;328(7442):750-4
references: 15044291
references: J Clin Endocrinol Metab. 2003 Jun;88(6):2706-13
references: 12788877
references: Lancet. 2006 Nov 11;368(9548):1696-705
references: 17098089
references: Diabetes. 2009 Apr;58(4):773-95
references: 19336687
references: Diabetologia. 1995 Mar;38(3):337-43
references: 7758881
references: Diabetes Care. 1996 Jun;19(6):580-6
references: 8725855
references: Best Pract Res Clin Endocrinol Metab. 2007 Dec;21(4):517-33
references: 18054733
references: Arch Intern Med. 2006 May 8;166(9):1021-6
references: 16682577
references: Hum Mol Genet. 2009 Jul 1;18(13):2388-99
references: 19386626
references: Diabetes Obes Metab. 2011 Jan;13(1):75-80
references: 21114606
references: Curr Diabetes Rev. 2009 Nov;5(4):266-75
references: 19925391
references: Diabetes Care. 2011 Jul;34(7):1463-8
references: 21593296
references: J Clin Endocrinol Metab. 2001 Aug;86(8):3717-23
references: 11502801
references: Postgrad Med. 2010 May;122(3):145-57
references: 20463424
references: Cell Metab. 2006 Mar;3(3):153-65
references: 16517403
references: J Investig Med. 2013 Jan;61(1):40-4
references: 23222002
references: Acta Endocrinol (Copenh). 1980 Nov;95(3):359-63
references: 7001832
references: Diabetes Care. 2010 Feb;33(2):428-33
references: 20103558
references: Mol Cell Endocrinol. 2009 Jan 15;297(1-2):127-36
references: 18786605
references: Diabetologia. 1983 Mar;24(3):141-7
references: 6341142
references: Endocrinology. 2009 Feb;150(2):580-91
references: 18818290
references: Horm Metab Res. 2000 Oct;32(10):424-8
references: 11069208
references: Diabetes. 2011 May;60(5):1599-607
references: 21441444